Skip to main content

Advertisement

Table 1 Clinical characteristics of the patients

From: Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA

Patient classification All patients (N = 50) EGFR-TKI naïve patients (N = 32) EGFR-TKI acquired-resistance patients (N = 18)
Age, year, median (IQR) 67.5 (59.8–73.3) 68.5 (58.3–73.8) 67.5 (62.7–73.5)
Sex, female 25 (50.0%) 14 (43.8%) 11 (61.1%)
Smoking status
 Non-smoker 25 (50.0%) 13 (40.6%) 12 (66.7%)
 Ex-smoker 14 (28.0%) 9 (28.1%) 5 (27.8%)
 Current smoker 11 (22.0%) 10 (31.3%) 1 (5.6%)
Tumor EGFR mutation
 Exon 19 deletion 22 (44.0%) 10 (31.3%) 12 (66.7%)
 L858R 15 (30.0%) 9 (28.1%) 6 (33.3%)
 Wild-type 13 (26.0%) 13 (40.6%) 0
Histology
 Adenocarcinoma 50 32 18
  1. EGFR-TKI epidermal growth factor receptor tyrosine kinase inhibitor; IQR interquartile range